


Insect medicines for colorectal cancer

A review of mechanisms, preclinical evidence, and future prospects

Xinyi Ao, MB^{a,b}, Xin Zhou, MM^{a,b}, Jianqin Liu, MM^{a,b}, Qian Wu, MB^{a,b}, Yanlin Yang, MB^{a,b}, Yali Liu, MB^{a,b}, Weian Hao, MB^{a,b}, Li Li, MM^{a,b}, Kaixuan Wang, MD^{a,c,*}, Zhi Li, MD^{a,b} 

Abstract

Colorectal cancer is recognized as the third most prevalent malignant tumor globally. The recommended treatment modalities, including surgery, radiotherapy, and chemotherapy, are frequently associated with severe side effects and high recurrence rates. Cancer experts are actively engaged in a global pursuit of safer and more efficacious treatment strategies for colorectal cancer (CRC). Insect medicine, a unique subset of traditional Chinese medicine, is characterized by their broad spectrum of therapeutic effects, which include antibacterial, anticoagulant, antithrombotic, and sedative actions. Insects are enriched with proteins, peptides, and amino acids. These compounds exhibit pharmacological activities, including anti-tumor effects, inhibition of cancer cell proliferation, induction of apoptosis in cancer cells, anti-inflammatory properties, and immunomodulation. Recent studies have revealed that certain traditional Chinese insect medicines, such as *Bombyx Batryticatus*, *Tubiechong*, and *Aspongopus chinensis* Dalls, demonstrate outstanding therapeutic efficacy in the treatment of CRC. The anti-CRC actions of these insect medicines are potentially mediated through mechanisms involving the Hedgehog and Wnt/ β -catenin signaling pathways, as well as immunomodulatory effects. Consequently, these insect medicines are proposed as a potential strategy for CRC treatment.

Abbreviations: CRC = colorectal cancer, HPLC = high-performance liquid chromatography, TCM = traditional Chinese medicine.

Keywords: colorectal cancer, insect medicine, pharmacological properties, protein peptides, signal transduction

1. Introduction

Colorectal cancer (CRC) ranks as the third most prevalent cancer globally and is the second leading cause of cancer-related mortality.^[1] Epidemiological data from the American Cancer Society indicate that the global incidence of CRC stands at 10.7%, with a mortality rate of 9.5%. Significantly, the incidence and mortality rates for men exceed those for women. Projections suggest that the global incidence of CRC may rise by approximately 63% by 2040, relative to 2020.^[2] In 2020, colorectal cancer (CRC) cases constituted 12.2% of all cancer diagnoses in China and accounted for 28.8% of the global incidence of this disease.^[3] Given these statistics, CRC has emerged as one of the significant challenges in public health. Typical clinical manifestations of CRC include dysfunction of the digestive system, characterized by symptoms such as bloating, abdominal pain, and abnormal stools.^[4] As CRC progresses, patients may develop systemic symptoms,

including anemia, malnutrition, and fever. The absence of pronounced symptoms in the early stages often results in many individuals being diagnosed at a more advanced stage of the disease. Consequently, early screening is paramount. The American Cancer Society advises that individuals at average risk begin regular screening at the age of 45. Should fecal tests, flexible sigmoidoscopy, or CT colonography yield abnormal results, a colonoscopy is recommended to complete the screening process.^[5]

The development of CRC is influenced by a combination of genetic, epigenetic, and environmental factors.^[6] Throughout the progression of CRC, the intestinal mucosa experiences a progressive transformation from normal tissue to adenoma and subsequently to cancer. Research highlights that crucial oncogenic signaling pathways serve as “initiators” in the process of carcinogenesis. Accumulated genetic mutations within the Wnt/ β -catenin, p53, and TGF- β /SMAD pathways disrupt the normal mechanisms of cellular growth, apoptosis, and DNA

XA, XZ, and JL contributed to this work equally.

This work was supported in part by the Science and Technology Program of Hospital of TCM, Southwest Medical University (no. 2022-CXTD-01), Luzhou Municipal Science and Technology Bureau (2024JYJ033), and Luzhou Municipal Government-Southwest Medical University Joint Project (2024LZXNYDJ112).

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

^a Department of Spleen and Stomach Diseases, the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China, ^b The Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Digestive System Diseases of Luzhou City, the Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China, ^c Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China.

* Correspondence: Kaixuan Wang, Department of Gastroenterology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China (e-mail: wangkaixuan224007@163.com).

Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ao X, Zhou X, Liu J, Wu Q, Yang Y, Liu Y, Hao W, Li L, Wang K, Li Z. Insect medicines for colorectal cancer: A review of mechanisms, preclinical evidence, and future prospects. *Medicine* 2025;104:11(e41873).

Received: 9 September 2024 / Received in final form: 17 February 2025 / Accepted: 26 February 2025

<https://dx.doi.org/10.1097/MD.00000000000041873>

repair, resulting in the uncontrolled proliferation of atypical and heterogeneous cancer cells.^[7] Epigenetics plays a crucial role in regulating gene expression, and research has highlighted gaps between specific gene expression patterns associated with CRC and the lack of corresponding genetic variations. Notably, microsatellite instability, a hallmark of certain CRC molecular subtypes, may arise from epigenetic silencing driven by hypermethylation of the MLH1 gene promoter. Global hypomethylation, which contributes to chromosomal instability, is frequently observed in CRC. Furthermore, miRNAs play a significant role in inhibiting protein expression at the post-transcriptional level, influencing numerous pathways associated with cancer. This modulation impacts virtually every stage of CRC, from its initiation through progression to metastasis.^[8] Environmental factors including overweight, obesity, physical activity, and dietary patterns have been demonstrated to be associated with the gut microbiome.^[9,10] The gut microbiome and its metabolic byproducts play a role in the pathogenesis of CRC by influencing the host's immune response and regulating intestinal inflammation. Alterations in the composition of the gut microbiome correlate with CRC risk. The detection of specific microbial markers across diverse populations indicates a potential connection between the composition of the gut microbiome and the risk of CRC.^[11,12] The pathogenesis of CRC is complex, influenced by the interplay of genetic, epigenetic, and environmental risk factors.

Current treatment approaches for CRC encompass both surgical and pharmacological interventions. The choice of surgical intervention depends on the stage and location of the cancer, as well as the patient's overall health. Early-stage cancers (stage 0 and stage 1 tumors) are typically managed through polypectomy or local excision during colonoscopy. In cases of advanced cancer, partial or total colectomy may be indicated, often including lymph node dissection.^[13] However, these procedures carry risks, including the potential for residual cancer and perforation. Pharmacological treatments for CRC encompass radiotherapy, chemotherapy, and targeted therapies.^[14] However, these interventions are often costly and associated with substantial side effects. Additionally, recent advances in immunotherapy, particularly the approval of 2 antibodies targeting programmed cell death protein 1, have provided new treatment options for patients with metastatic colorectal cancer (mCRC) exhibiting high microsatellite instability and mismatch repair deficiencies (dMMR).^[15] However, these therapies are associated with severe side effects and potential issues related to immune tolerance, underscoring the critical need for the development of safer and more effective treatment modalities.^[16]

Traditional Chinese medicine, leveraging its natural medicinal properties, exhibits unique benefits in the realm of cancer therapy.^[17] Insect medicine, a hallmark of traditional Chinese medical practice, has been employed for millennia to address complex health conditions. Insect medicine is considered to be flesh and blood in Chinese (bodily healing, physical coherence, and equilibrium), Which has distinctive efficacies such as activating circulation to remove blood stasis, removing swelling, fostering tissue regeneration, harmonizing qi and blood, as well as fortifying the body's fundamental health. Advancements in modern pharmacological research methodologies have facilitated the identification of the active constituents in insect medicines. Studies have shown that small molecule peptides present in centipedes may suppress the proliferation of liver cancer cells by regulating the tyrosine phosphorylation pathway. Extracts derived from leeches are shown to inhibit retinoblastoma by impeding the proliferation of WERI-RB-1 cells.^[18] A novel anticancer protein EPS72, purified from tubiechong, has been shown to suppress human lung cancer A-549 cells by inducing apoptotic death characterized by cell detachment.^[19] This review consolidates recent findings on the active constituents and potential mechanisms of insect medicines in the fight against CRC. It aims to offer fresh perspectives for devising

novel, integrated therapeutic approaches for this malignancy. Insect medicines, known for their multi-target effects, low toxicity, and minimal side effects in oncological treatments, have emerged as a significant resource for developing novel anti-CRC drugs.^[20] Owing to their biological similarity to humans, insect medicines exhibit potential advantages in treating CRC, characterized by high absorption and utilization rates in the human body. This may contribute significantly to their efficacy in CRC therapy.^[21]

2. Materials and methods

2.1. Sources of literature

This review was conducted through a systematic search of databases such as China National Knowledge Infrastructure (CNKI), WANFANG DATA, PubMed, Google Scholar, and Web of Science. The search spanned literature published from January 1, 2000, to March 31, 2024, aiming to evaluate advancements in the research on the use of insect medicine in treating CRC.

2.2. Retrieval methods

The search strategy employed both Chinese and English keywords and their combinations: ("Earthworm" OR "Scorpion" OR "Bombyx Batryticatus" OR "Centipede" OR "Leech" OR "Dilong" OR "Quanxie" OR "Jiuxiangchong" OR "Tubiechong" OR "Jiangcan" OR "Wugong" OR "Shuizhi") AND ("Tumor" OR "Cancer" OR "Colorectal Cancer" OR "Zhongliu" OR "Aizheng" OR "Jiezhichangai"). A "fuzzy" matching option was selected to enhance the search effectiveness, complemented by manual retrieval to ensure no relevant studies were overlooked. Data analysis was conducted using Excel 2021.

2.3. Criteria for literature inclusion and exclusion

2.3.1. Inclusion criteria.

2.3.1.1. Required literature includes experimental research on applying single-herb insect medicine in vitro cell lines or animal models for CRC treatment.

2.3.1.2. Research must provide detailed data on the efficacy, pharmacological effects, toxicity, and safety of the insect medicine.

2.3.1.3. Research must be published in peer-reviewed scientific journals.

2.3.1.4. Publications must be authored in either English or Chinese.

2.3.2. Exclusion criteria.

2.3.2.1. Opinion pieces, editorials, conference abstracts, or case reports.

2.3.2.2. Studies with insufficient methodological rigor or incomplete result reporting.

2.3.2.3. Literature directly on clinical trials or case studies.

2.3.2.4. Duplicate publications or secondary literature analyses.

2.3.2.5. Research not specifying the insect medicine component or not tested within CRC models.

Initial screening will involve assessing titles and abstracts to exclude studies that do not meet the inclusion criteria, followed by full-text reviews of potentially relevant studies for further assessment. (Fig. 1 illustrates the flow chart of study selection,




Figure 1. Flow chart of study selection.

providing a visual summary of the steps involved in screening and including studies in this analysis)

3. Overview of insect medicine

3.1. Historical origins of insect medicine

The history of insect medicine dates back to oracle bone inscriptions from four thousand years ago. These inscriptions include references to medicinal animals such as snakes, musk deer, and rhinoceroses, indicating the early origins of the use of insects, in medicinal practices. In the Spring and Autumn and Warring States periods, ancient literary works, such as the “Classic of Mountains and Seas” and the “Classic of Poetry,” offered detailed accounts of animal-based medicines.^[22] The “Shennong Bencao Jing,” regarded as the earliest existing pharmacological treatise, extensively documents various insect medicines. It represents the initial systematization of entomotherapy, providing a crucial foundation for the development of theories and practices in traditional Chinese medicine. During the Eastern Han Dynasty, Zhang Zhong jing used insect medicine to treat conditions such as mental disturbances associated with blood stasis in the lower energizer, acute abdominal pain, and various gynecological disorders. This practice further validated

the effectiveness and significance of insect medicine in clinical settings. In the Ming Dynasty, Li Shizhen’s “Compendium of Materia Medica” comprehensively and systematically encapsulated the application experiences of insect medicine, elevating its study to unprecedented levels. This work solidified the role of insect medicine as an indispensable component within the repository of Traditional Chinese Medicine. To this day, insect medicines retain their unique value and demonstrate substantial potential in contemporary medical research and clinical applications.

3.2. The characteristics of insect medicine in traditional Chinese medicine

Insect medicines, also called zoological drugs, primarily include dried medicinal animals (excluding internal organs), specific body parts, secretions, excretions, and substances produced in both normal and pathological states. These substances undergo specific processing techniques to form a vital component of TCM therapeutic practice.^[22] In Traditional Chinese Medicine theory, the etiology of CRC is attributed to the invasion of toxins, obstruction of qi and blood, phlegm and blood stasis, and the gathering of cancer toxins over time. Cancer toxins are

Table 1**The application of modern analytical techniques in insect medicine**

No	Insect medicine	Sample type	Analytical techniques	Compounds	reference
1	Scorpion	Lyophilized substances	GC-MS	Thirteen free proteinogenic amino acids (Ile, Phe, Met, Asp, Thr, Tyr, Leu, Val, Ser, Glu, Gly, Pro, Ala) and 3 non-proteinogenic amino acids (Tau, β -Ala, GABA)	[25]
2		live specimens	LC-MS	Scorpion toxin family – omegascorpins	[29]
3		live specimens	MS	A novel anticancer protein – leptulipin	[30]
4	Centipede	live specimens	LC-MS-MS	A novel allergen – Scm5(comprising 210 amino acids)	[31]
5		live specimens	HPLC-MS	molecular weight 1018.997 Da peptide sequence RAQNHVCK	[32]
6		dried forms	nanoRPLC-MS/MS	Ninety-two proteins	[27]
7	Leech	medicinal slices	UPLC- HR- MS	A novel thrombin inhibitor peptide with the sequence SYELPDGQVIGENER	[28]
8		live specimens	LC- MS	A novel antiplatelet protein – pigrin	[33]
9	Tubiechong	ultrafine powders	HPLC	Six free proteinogenic amino acids(Gly, Arg, Ala, Pro, His, Lys)	[25]
10		live specimens	LC- MS	The active peptide – DP-17 with the sequence DAVPGAGPAGCHPGAGP	[34]
11	Aspongopus chinensi	live specimens	HPLC	molecular weight 2853.3Da inhibits the proliferation of gastric cancer cells SGC-7901	[35]
12		methanol extracts	GC- MS	oleic acid, palmitic acid, z-11-hexadecenoic acid, Threitol, stearic acid, 2-hexenoic acid, 1-(14-methylhexadecanoyl) pyrrolidine	[36]
13	Bombyx Batryticatus	extraction solutions	UHPLC-Q-TOF MS	Lumichrome, Demethylated Chlorophyll A p-Coumaroyl Esters 4'-O- β -D-Pyrano-glucoside	[37]

Table 2**Protein/peptide in insect medicine**

No	Insect medicine	Protein/peptide name	Relative molecular mass/da	Amino acid/peptide sequence	Reference
1	Earthworm	F1	24.6	VVGGSDTTIGQYPHQLSLRVTG	[40]
2		F2	26.8	IIGGSNASPGFEPWQLSQTRG	[40]
3		F3	28.2	VIGGTNASPGFEPWQLSQQRQ	[40]
4		F4	25.4	VIGGTDAAPGEPWQLSQTR	[40]
5		F5	33.1	IVGGIEARPYEFPWQVSVRRKS	[40]
6		F6	33	IVGGIEARPYEFPWQVSVRRKS	[40]
7		EFE	29.5	RKKGASWFWPWSVKKR	[41]
8		D2(8)	23335.14	IVGGYTCA	[42]
9		Band13	15983.48	GVHLTDAEKA	[42]
10		Band9	23334.69	GVHLTDAEKA	[42]
11		Band7	33317.19	GVVISIANQKGGVG	[42]
12		ARSP1	28000	N-terminal 25 Amino Acid Sequence – IIGGTNASPGFEP-WQLSQTRGGSHS	[43]
13		F-1	535.27	Ac-AMVSS	[44]
14		F-2	519.27	Ac-AMVGT	[44]
15		VQ-5	519.277	VSSVQ	[45]
16		AQ-5	535.218	AMAQQ	[45]
17		GGNG2	1598.6	GKCAQQWAIHAAGNGOH	[46]
18		GGNG3	1824.8	PKCSRWAHSCGGNGOH	[46]
19		GGNG1	1756	ARPKCAGRWAIHSCGGNGOH	[46]
20	Scorpion	ANTP	6280	N-terminal 25 Amino Acid Sequence – VRDGYIADKNCAYFCGR-NAYCDDE	[47]
21		BMK 9(3)-1	7020	GRDAYIADSENCYPFCGANPN	[48]
22		BMK 9(3)2	7037	GRDAYIADSENCYPYTCALNP	[48]
23		Pi5	3334	VAKCSTSECGHACQAGCRNSGCRYGSCICVGC	[49]
24		Pi6	3126.5	VDACYEACMHMHMSDDCIEACKNPVPP	[49]
25		AEP	8290	N-terminal 25 Amino Acid Sequence – DGYIRGSDNCKVSCLL-GNEGCNKECRAYGASYGYCWTVKLAQDCEGLPDT	[50]
26	Centipede	scolopin1	2593.9	FLPKMSTKLVRPYRRGTDYH	[51]
27		scolopin2	3017.6	GILKFMHLRGTKVYKMRTLKRSH	[51]
28		scolopendrin I	4498	/	[52]
29		scolopendrasin V	3723.9	YYGGGYKYKHWGCR-NH2	[53]
30		scolopendrasin VII	3414.1	FCTCNVKGFNKNRGYP	[53]
31		LBLP	2757.6	RMKKLGNHK VSCERNTRKCRKA	[54]
32	Tubiechong	ES-termicin	4055.58	ACDFQQCWVTCQRQYSINFISARCNDSVCVCTFRT	[55]
33		DP17	1430	DAVPGAGPAGCHPGAGP	[34]
34		LL8	NA	LAPAPGTL	[56]
35		AR-9	816.3	AVFPSIVGR	[57]
36	Bombyx Batryticatus	BB octapeptide	885	AspProAspAlaAspIleLeuGln	[58]
37		BCCI	13,973.63	N-terminal Amino Acid Sequence – VRNKRQSNDD	[59]
38	Aspongopus Chinensis Dalls	Cc AMP1	1 997.37	SKITDILAKLGKVLAVH	[60]

identified as the primary pathological mechanism driving the onset and progression of CRC. Consequently, the core of the treatment strategy focuses on detoxification and anti-cancer therapies.^[23] Owing to their potent medicinal properties, insect medicines are considered capable of penetrating deep into the body, directly targeting lesions, and exhibiting the ability to detoxify and remove stasis.^[21] Consequently, insect medicines are increasingly being utilized in the treatment of CRC, aiming to disperse the stubborn malignancies associated with tumors.

4. Component analysis of insect medicines

Insect medicines encompass a diverse array of types with intricate compositions. The scientific foundations underlying their efficacy and toxicity are not yet fully clarified. Consequently, it is crucial to explore and develop advanced techniques for the effective analysis of active components in these medicines. At present, high-performance liquid chromatography (HPLC), thin-layer chromatography, mass spectrometry, and their associated hybrid techniques are extensively utilized in the analysis of insect medicines.^[24] These techniques are favored due to their high sensitivity, specificity, and capability to analyze complex mixtures of compounds. Cai et al^[25] successfully developed an HPLC fingerprint for free amino acids in the ultrafine powder of Tubiechong using HPLC, marking 24 common peaks. According to the 2020 edition of the “Chinese Pharmacopoeia,” more than one hundred types of medicinal materials and their formulations, which utilize active components from animal medicines, are qualitatively identified using thin-layer chromatography. Yang et al^[26] utilized GC-MS technology to identify 13 free protein amino acids and 3 free non-protein amino acids from scorpion extracts. Chen et al^[27] identified 92 proteins in centipede extracts using nanoRPLC-MS/MS. Huang et al^[28] identified a novel anticoagulant peptide with a molecular weight of 1790 Da from leech extracts, utilizing affinity chromatography coupled with ultra-high performance liquid chromatography-high resolution mass spectrometry. The peptide sequence is SYELPDGQVITIGNER. The integration of these advanced analytical techniques holds significant scientific importance for the in-depth investigation of the active components in insect

medicines. (Please refer to Table 1 for details, Table 1 presents the application of various modern analytical techniques in different insect medicines. Techniques such as GC-MS, LC-MS, and HPLC have been employed to identify a range of compounds, including free proteinogenic amino acids and novel anticancer proteins found in scorpions.^[25,27–37])

5. Mechanisms of anti-CRC activity in insect medicine and its active components

5.1. Types of proteins and peptides

Proteins and peptides, serving as crucial active components in insect medicine.^[38,39] (Please refer to Table 2 for details, Table 2 outlines the proteins and peptides identified in insect medicine, listing their relative molecular mass and amino acid sequences. These proteins and peptides have been shown to play critical roles in the therapeutic effects of insect-derived treatments.^[40–60]), play key biological roles in organisms. Proteins, complex biomolecules found ubiquitously across all organisms, are composed of amino acid residues connected by peptide bonds. They are essential for executing primary cellular functions and maintaining the structural and functional integrity of an organism's tissues and organs.^[61] Peptides, which are shorter amino acid chains linked by peptide bonds, perform diverse functions within organisms. These functions include acting as carriers for drug delivery,^[62,63] regulating immune responses,^[64] and contributing to disease treatment. Proteins and peptides exhibit anti-cancer potential through various mechanisms. They directly interact with cancer cell membranes, causing membrane disruption and cell death.^[65] Additionally, they inhibit tumor growth, angiogenesis, and metastasis, thereby hindering the development and spread of tumors. These substances activate the immune system to combat tumors, thereby enhancing the body's natural defenses. They also suppress cancer cells by inducing oxidative stress and various forms of cell death.^[66]

Since 1983, researchers have identified 48 types of earthworm protein peptides, including their names, relative molecular weights, amino acid sequences, isoelectric points, and biological activities. Notable among these are lumbrikineses,




Figure 2. The mechanism of action of protein/peptide in insect medicines.

which are fibrinolytic enzymes, as well as antimicrobial peptides and nuclease-like proteins.^[67] Arkadiusz Czerwinka et al^[68] isolated protein-carbohydrate active molecules (AF) from earthworm coelomic fluid. These molecules exhibited inhibitory effects on CRC cells in vitro while having no impact on the survival and morphology of normal human colon epithelial cells (CCD 841 CoTr). Specifically, AF significantly reduces mitochondrial metabolism in HT-29 cancer cells, disrupts the cell cycle, and induces apoptosis by activating caspase-3 precursors. Additionally, AF inhibits the activity of the human 20S proteasome. Xie et al^[43] extracted and identified protein components with anti-tumor activity from the earthworm *Eisenia fetida*. These protein components demonstrate significant selective inhibitory effects on specific human cancer cell lines, including SY5Y, K562, MGc803, and HeLa. Notably, from these extracts, Apoptosis-Related Serine Protease 1 (ARSP1) was isolated and identified. ARSP1 induces apoptosis in HCT-116 human CRC cells, effectively killing them. Furthermore, in animal models, ARSP1 has been shown to significantly prolong the survival of tumor-bearing mice.

Centipede venom, primarily found in the venomous secretion of centipedes, consists mainly of enzymes and peptides.^[69] Antimicrobial peptides in centipede venom not only exhibit lethal activity against bacteria and fungi but also demonstrate inhibitory effects on certain cancer cells.^[70] Lee et al^[71] discovered that Scolopendrasin VII interacts with phosphatidylserine, a prevalent component on cancer cell surfaces, inducing necrotic cell death. This interaction demonstrates selectivity towards cancer cells, with minimal effects on the viability of non-cancerous cells. Zhao et al^[72] discovered that a centipede polysaccharide-protein complex enhances tumor immune responses by downregulating the arachidonic acid (AA) metabolic pathway in tumor-associated macrophages, consequently inhibiting tumor growth in vivo.

Scorpion venom is a complex secretion emitted by entire scorpions, comprised primarily of protein and non-protein components. It possesses the potential to induce paralysis or even death in humans. Recent research has further elucidated that scorpion venom contains a variety of scorpion venom peptides. These peptides are the crucial active components that mediate the

venom's pharmacological actions.^[73] He et al^[74] discovered that the East Asian scorpion venom toxin (BMK) exhibits an inhibitory effect on human CRC cells Caco-2 within a concentration range of 10 to 40 µg/mL. This inhibitory effect strengthens with increased concentration and extended exposure duration. Furthermore, the mechanism by which BMK inhibits the growth of Caco-2 cells may be associated with its promotion of lymph transformation and its cytotoxic effects.

Tan et al^[75] isolated a protein component (CHP) from *Aspongopus chinensis* Dallas, which exhibits significant anti-proliferative and pro-apoptotic effects on cancer cells in a concentration-dependent manner. Additionally, it demonstrates anti-tumor activity in vivo. (Fig. 2 demonstrates the mechanism of action of various proteins and peptides found in insect medicines, such as earthworm coelomic fluid (AF and ARSP1), centipede venom (Scolopendrasin VII), and scorpion venom (BMK))

5.2. Trace elements

Trace elements, such as iron, selenium, magnesium, copper, and molybdenum, though present in minor quantities in insect medicine, play a significant role in its anti-tumor effects.^[76,77] They participate in tumor therapy through multiple mechanisms, such as regulating oxidation-reduction reactions, influencing the cell cycle, and activating immune responses.^[77] The trace elements iron and copper have been detected in insect medicines, including *Tubiechong*, *Bombyx Batryticatus*, scorpions, centipedes, leeches, and *Aspongopus chinensis*. Iron is a critical driver of ferroptosis, an iron-dependent cell death mechanism. It induces cell death through the promotion of polyunsaturated fatty acids lipid peroxidation, accumulation of iron ions, and formation of lipid peroxides. This mechanism holds potential application value in the treatment of CRC.^[78] The regulation of ferroptosis involves various molecular pathways, such as lipoxygenases and long-chain fatty acid CoA synthetase (ACSL4). These pathways increase cellular sensitivity to ferroptosis by integrating polyunsaturated fatty acids into the cell membrane.^[79] Additionally, antioxidant defense mechanisms, notably the activity of glutathione peroxidase (GPX4), play a critical role in ferroptosis.


















Figure 3. The mechanism of action of trace elements in insect medicines.

Table 3
Alkaloids in insect medicine

No	Insect medicine	Compounds	Chemical structure	Molecular formula	Molecular weight	Reference
1	Aspongopus chinensis Dalls	valerolactam		C ₅ H ₉ NO	99	[89]
2		2-pyridone		C ₅ H ₅ NO	95	[89]
3		N-(2-hydroxyethyl) succinimide		C ₆ H ₉ NO ₃	143	[89]
4		indole-3-carboxylic acid		C ₉ H ₇ NO ₂	161	[89]
5		nicotine		C ₁₀ H ₁₄ N ₂	162	[89]
6		2-quinolinol		C ₉ H ₇ NO	145	[89]
7		choline		C ₅ H ₁₄ NO ⁺	104	[89]
8		indole-3-aldehyde		C ₉ H ₇ NO	145	[89]



(Continued)

Table 3
(Continued)

No	Insect medicine	Compounds	Chemical structure	Molecular formula	Molecular weight	Reference
9		transthorine		C ₁₀ H ₇ NO ₃	189	[89]
10		2-pyrrolidinone		C ₄ H ₇ NO	85	[89]
11	Tubiechong	3-indolepropionic acid		C ₁₁ H ₁₁ NO ₂	189	[90]
12		3-acetamido-5-acetylfuran		C ₈ H ₉ NO ₃	167	[90]
13		3-acetamido-5-acetyl		C ₁₂ H ₁₁ I- ₃ N ₂ O ₄	627	[90]
14		N-[2-(4-hydroxyphenyl)ethyl] butanamide		C ₁₂ H ₁₇ NO ₂	207	[90]

(Continued)

Table 3
(Continued)

No	Insect medicine	Compounds	Chemical structure	Molecular formula	Molecular weight	Reference
15		3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihydropyridin-2(1H)-one		C ₁₃ H ₁₃ NO ₃	231	[90]
16	Scorpion	Trigonelline		C ₇ H ₇ NO ₂	137	[91]
17		scorpionine A	NA	NA	NA	[91]
18		scorpionine B	NA	NA	NA	[91]
19		tenidine	NA	NA	NA	[91]
20		1-stearoyl-glycerol-3-phosphorylcholine	NA	NA	NA	[91]

Inhibition of GPX4 can be facilitated by specific drugs, such as Erastin and RSL3, which demonstrate potential in curbing the growth and survival of CRC cells.^[80]

Selenium, present in insect medicines like tabanus and earthworms, plays a multifaceted role in tumor therapy. The mechanisms of action of selenium include regulating the immune system, providing antioxidant and cell-protective functions, influencing microRNAs and hypoxia-inducible factors, participating in DNA repair, activating the Nrf2 pathway, and exerting anti-inflammatory effects. By enhancing the activation and proliferation of B cells and T cells, selenium promotes the body's anti-tumor immune response.^[81] As a component of selenoproteins, selenium's antioxidant properties help mitigate cellular damage induced by free radicals and inhibit tumor growth by shielding cells from oxidative stress.^[82] Furthermore, selenium modulates tumor angiogenesis, growth, and drug resistance by regulating microRNAs associated with tumor growth, such as miR-210 and miR-155, and hypoxia-inducible factors, including HIF-1α and HIF-2α.^[83] Selenium also contributes to DNA repair mechanisms, enhancing cellular repair capabilities against chemotherapy-induced DNA damage,^[84] by activating the Nrf2 pathway, selenium boosts cellular antioxidant and detoxification abilities, thus inhibiting tumor cell growth and survival, and enhancing the efficacy of chemotherapy drugs.^[85] Furthermore, selenium's anti-inflammatory properties aid in reducing inflammatory responses within the tumor microenvironment, further impeding tumor progression.^[86] Studies have shown that serum selenium levels below 80 μg/L may elevate the risk of CRC. Conversely, higher

concentrations of selenoprotein P (PSELENOP) correlate with a reduced risk of CRC, with particularly significant effects observed in women.^[87] Therefore, regulating selenium intake and optimizing selenium status could potentially exert a positive impact on the prevention and treatment of CRC. (Fig. 3 shows the mechanism of action of trace elements present in insect medicines, detailing how they contribute to the therapeutic effects.)

5.3. Alkaloids

Alkaloids, a class of nitrogen-containing organic compounds, have been extensively researched for their applications in tumor therapy. These compounds are known to inhibit tumor cell proliferation, induce apoptosis, suppress angiogenesis, block signal transduction, alter the tumor microenvironment, and promote cell differentiation.^[88] Four alkaloids have been identified in whole scorpion extracts: 1-stearoyl-glycerol-3-phosphocholine, trigonelline, scorpionine A, and scorpionine B. (Please refer to Table 3 for details, Table 3 summarizes the alkaloids found in insect medicine, including their chemical structures, molecular formulas, and molecular weights. These alkaloids are important for their pharmacological activities.^[89–91]). Notably, the trigonelline, also present in fenugreek seeds and coffee beans, exhibits significant anti-tumor activity.^[92,93] Sun et al^[94] demonstrated that trigonelline effectively inhibits the proliferation, migration, invasion, and colony formation of HCT116 and SW480 cells by suppressing the Hedgehog signaling pathway. Furthermore, Li et al^[95]




Figure 4. The mechanism of action of alkaloids in insect medicines.

Table 4
Selected insect medicines with anti-CRC activity in preclinical studies

No	Insect medicine	Active component	Model/cell line	Key findings	Reference
1	Earthworm (<i>E. fetida</i>)	ARSP1 protein	HCT-116 xenograft	Induces apoptosis, prolongs survival	[43]
2	Scorpion (<i>B. martensii</i>)	BMK toxin	Caco-2 (in vitro)	Inhibits proliferation, promotes lymph transformation	[74]
3	Centipede (<i>S. subspinipes</i>)	Scolopendrasin VII	Various tumor lines	Membrane disruption, Selective necrotic cell death	[71]
4	Aspongopus chinensis	CHP fraction	H22-bearing mice	Anti-proliferative, proapoptotic in vivo	[75]

discovered that trigonelline significantly inhibits the growth of colorectal tumors both in vivo and in vitro by targeting and suppressing the linc ROR-Wnt/β-catenin signaling axis in CRC. Further studies have identified 21 alkaloids in both Tubiechong and its whole-body ethanol extract. Notably, alkaloid 3, isolated from the ethyl acetate extract of Tubiechong, demonstrated varying degrees of inhibition on Colon38 and HCT-116 cells.^[96,97] (Fig. 4 illustrates the mechanism of action of alkaloids in insect medicines, highlighting their roles in the pharmacological activities of these treatments.)

6. In vitro, preclinical, and clinical evidence

6.1. In vitro studies

Most evidence for insect medicines against CRC arises from in vitro experiments. Earthworm extracts demonstrate selective inhibitory activity against CRC cell lines (HCT-116, HT-29), potentially through apoptosis induction.^[43,68]

6.2. Preclinical studies

Several in vivo studies have further elucidated the anti-CRC potential of insect-based Traditional Chinese Medicines. For instance, extracts from *Eisenia fetida* significantly inhibited tumor growth in xenograft mice, with one isolated protein (ARSP1) inducing apoptosis in CRC cells and prolonging animal survival.^[43] Similarly, scorpion venom and centipede-derived peptides have demonstrated notable tumor suppression effects

in murine models by modulating immune responses and inducing necrosis.^[72,74] (Please refer to Table 4 for details, Table 4 summarizes representative preclinical studies on insect medicines for CRC, detailing the insect source, active components, experimental models, and key anticancer findings.^[43,71,74,75])

6.3. Clinical studies

Due to our exclusion criteria, direct clinical reports were not included. Limited pilot clinical or case-based studies have suggested potential benefits of insect medicines for CRC,^[21] but large-scale randomized controlled trials remain lacking. Further investigation is warranted to confirm efficacy and safety in clinical settings.

7. Discussion

In CRC research, insect medicine is gaining attention due to its rich array of bioactive components, including protein peptides, trace elements, and alkaloids. These components have been shown to directly interact with cancer cell membranes, induce cell death, and inhibit tumor growth, angiogenesis, and metastasis through various mechanisms, thus impeding further tumor progression. Research on iron has highlighted its critical role in promoting cancer cell death through iron-dependent mechanisms, known as ferroptosis, providing new perspectives for CRC treatment. Furthermore, these elements also activate the immune system, enhance natural defenses, and combat tumor cells through the induction of oxidative stress and various cell

death mechanisms. Although initial research suggests potential anti-tumor effects of these active components, their safety, efficacy, and specific applications in cancer therapy need to be validated through additional clinical trials and mechanistic studies. Such research lays the groundwork for developing novel anti-cancer strategies and guides the direction of future cancer treatment studies.

In Traditional Chinese Medicine, the use of insect medicine in the treatment of CRC has a long history. However, due to concerns over the unknown toxicity profile of insect medicines, it becomes increasingly important to rigorously assess their safety and potential toxicity as modern toxicology research advances. Research indicates that the hepatorenal toxicity of centipedes is significant, and the dosage range linked to liver damage may be between 2 to 7 centipedes per day.^[98–100] The primary harmful substances found in Tubiechong are heavy metals and aflatoxins, which can lead to damage to the skin and its appendages, as well as the nervous and circulatory systems. Active components found in Bombyx Batryticatus, including ammonium oxalate and Beauveria bassiana toxin, have been confirmed to be toxic. These substances can induce symptoms such as limb tremors, abdominal pain, and diarrhea, impacting both the nervous and digestive systems. Toxicological research on scorpion venom has demonstrated that it can induce liver and kidney damage, neurotoxic reactions, and respiratory suppression. Consequently, toxicological research is essential in determining the safety of insect medicine for clinical use. This includes identifying potential harmful components, assessing toxicity at various dosages, and elucidating toxicological mechanisms. Considering the multiple active components in insect medicine, interactions among them could result in unforeseen toxic effects. Interactions among components can either enhance or reduce the toxicity of individual elements, making the study of these compound effects vital for evaluating the overall safety of a medication. Furthermore, the potential long-term toxicity is a critical consideration in the safe utilization of insect medicine. While some components might show minimal toxicity in the short term, prolonged use could result in chronic health issues, such as liver or kidney damage.

Literature reviews indicate the clinical dosages for centipedes range from 3 to 5 grams when decocted and 0.6 to 1 gram when administered as a powder; For scorpions, modern clinical usage typically ranges from 3 to 6 grams, with common dosages up to 10 grams; Earthworms and Tubiechong commonly use doses of 3 to 60 grams and 6 to 12 grams, respectively. These figures offer guidelines for dosing insect medicine in the treatment of CRC, with an emphasis on ensuring safety.

8. Conclusion and future prospects

This review delves into the advancements in using insect medicine for CRC treatment, with a focus on the anti-tumor mechanisms of its active components. These include inducing apoptosis, inhibiting cell proliferation, blocking angiogenesis, and activating immune responses. The mechanisms span various signaling pathways, including Hedgehog, Wnt/ β -catenin, and immune regulatory pathways, offering a molecular foundation for the anti-tumor efficacy of insect medicine.

While existing laboratory studies and preliminary clinical trials provide support for the use of insect medicine, significant challenges remain. The safety, toxicity, and effective dosages require further validation through extensive clinical research. Moreover, the development of efficient extraction and purification techniques for active components, and a clear elucidation of their molecular mechanisms, are imperative. Future research should focus on exploring the interactions and synergistic effects between insect-based Chinese medicine and traditional anti-cancer drugs, and its potential role in comprehensive anti-cancer therapy.

Author contributions

Investigation: Qian Wu, Yanlin Yang, Yali Liu, Weian Hao.

Supervision: Zhi Li, Li Li, Kaixuan Wang.

Writing – original draft: Xinyi Ao, Xin Zhou.

Writing – review & editing: Jianqin Liu.

References

- [1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72:7–33.
- [2] Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. *Gut.* 2023;72:338–44.
- [3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209–49.
- [4] Yde J, Larsen HM, Laurberg S, Krogh K, Moeller HB. Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options. *Int J Colorectal Dis.* 2018;33:683–94.
- [5] Shaikat A, Levin TR. Current and future colorectal cancer screening strategies. *Nat Rev Gastroenterol Hepatol.* 2022;19:521–31.
- [6] Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. *Gastroenterol Rep (Oxf).* 2022;10:goac035.
- [7] Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. *Int J Mol Sci.* 2020;22:130.
- [8] Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. *Nat Rev Gastroenterol Hepatol.* 2020;17:111–30.
- [9] Himbert C, Stephens WZ, Gigic B, et al. Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients. *Am J Cancer Res.* 2022;12:4789–801.
- [10] Song M, Chan AT. Environmental factors, gut microbiota, and colorectal cancer prevention. *Clin Gastroenterol Hepatol.* 2019;17:275–89.
- [11] Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. *Nat Rev Immunol.* 2021;21:653–67.
- [12] White MT, Sears CL. The microbial landscape of colorectal cancer. *Nat Rev Microbiol.* 2024;22:240–54.
- [13] Alese OB, Zhou W, Jiang R, et al. Predictive and prognostic effects of primary tumor size on colorectal cancer survival. *Front Oncol.* 2021;11:728076.
- [14] Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. *Lancet.* 2019;394:1467–80.
- [15] Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. *Int J Biol Sci.* 2021;17:3837–49.
- [16] Kohne CH. Successes and limitations of targeted cancer therapy in colon cancer. *Prog Tumor Res.* 2014;41:36–50.
- [17] Kong MY, Li LY, Lou YM, Chi HY, Wu JJ. Chinese herbal medicines for prevention and treatment of colorectal cancer: from molecular mechanisms to potential clinical applications. *J Integr Med.* 2020;18:369–84.
- [18] Li YY, Zheng YL, Liu XL, Li H, Ma HJ. The inhibitory effect of leech extract on human retinoblastoma cells. *Int Eye Sci.* 2020;1693–8.
- [19] Wang FX, Wu N, Wei JT, et al. A novel protein from Eupolyphaga sinensis inhibits adhesion, migration, and invasion of human lung cancer A549 cells. *Biochem Cell Biol.* 2013;91:244–51.
- [20] Chen JF, Wu SW, Shi ZM, Hu B. Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. *Chin Med.* 2023;18:14.
- [21] Zhaofeng T, Yuanfu QI, Xiurong LI. Application of insect drugs in neoplastic diseases. *China J Chin Med.* 2015;06:782.
- [22] Xiang G. Prospects and research situation of insect-drugs. *China J Tradit Chin Med Pharm.* 2010;06:807.
- [23] Hai-Bo C, Liu LI, Mian-Hua WU, Zhong-Ying Z. Discussion on treating colorectal cancer of the pathogenesis theory of cancer toxin. *Lishizhen Med Mater Med Res.* 2017;10:2487.
- [24] Yin-Fang C, Chang-Hua Z, Xue-Xin W, Ri-Yue YU, Xiu-Ying TU. Research progress on detection and analysis of proteins and amino acids in animal medicine. *Lishizhen Med Mater Med Res.* 2017;01:186.
- [25] Ping C, Dan W, Juan X, Shui-Han Z, Guang-Xian C. HPLC fingerprint of free amino acids in micropowder of eupolyphaga. *Chin Tradit Patent Med.* 2011;33:1645–8.
- [26] Qin Y, Rui T, Hongchao W, et al. Analysis of fatty acids and amino acids in scorpion by gas chromatography mass spectrometry. *J Chin Inst Food Sci Technol.* 2016;10:174.

- [27] Chen X, Wen HM, Liu R, et al. Analysis of extracted proteins from centipede using nano-scale reverse phase liquid chromatography-tandem mass spectrometry. *Chin J Anal Chem*. 2014;42:239–43.
- [28] Huang Q, Gao Q, Chai X, et al. A novel thrombin inhibitory peptide discovered from leech using affinity chromatography combined with ultra-high performance liquid chromatography-high resolution mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2020;1151:122153.
- [29] Romero-Gutierrez T, Peguero-Sanchez E, Cevallos MA, Batista CVF, Ortiz E, Possani LD. A deeper examination of thorellius atrox scorpion venom components with omic technologies. *Toxins (Basel)*. 2017;9:399.
- [30] Rezaei A, Asgari S, Komijani S, et al. Discovery of leptulipin, a new anticancer protein from the Iranian Scorpion, *Hemiscorpius lepturus*. *Molecules*. 2022;27:2056.
- [31] Lan XQ, Zhao F, Wang QQ, et al. Isolation and characterization of the major centipede allergen Sco m 5 from scolopendra subspinipes mutilans. *Allergol Int*. 2021;70:121–8.
- [32] Hu YX, Liu Z, Zhang Z, et al. Antihepatoma peptide, scolopentide, derived from the centipede scolopendra subspinipes mutilans. *World J Gastroenterol*. 2023;29:1875–98.
- [33] Ren SH, Liu ZJ, Cao Y, et al. A novel protease-activated receptor 1 inhibitor from the leech *Whitmania pigra*. *Chin J Nat Med*. 2019;17:591–9.
- [34] Jiang S, Dong PP, Li HR, et al. Study on lipid-lowering mechanism of active peptide DP17 from *Eupolyphaga steleophaga* in hyperlipidemia rats. *China J Chin Mater Med*. 2020;45:5265–72.
- [35] Chen XM, Zhang SQ, Cao ML, Guo JJ, Luo R. Isolation of peptide inhibiting SGC-7901 cell proliferation from *aspongopus chinensis dallas*. *Int J Mol Sci*. 2022;23:12535.
- [36] Tan J, Tian Y, Cai R, Luo R, Guo J. Chemical composition and antiproliferative effects of a methanol extract of *aspongopus chinensis dallas*. *Evid Based Complement Alternat Med*. 2019;2019:2607086.
- [37] Wang Q, Wang R, Zheng C, et al. Anticonvulsant activity of *bombyx batryticatus* and analysis of bioactive extracts based on UHPLC-Q-TOF MS/MS and molecular networking. *Molecules*. 2022;27:8315.
- [38] El-Tantawy NL. Helminthes and insects: maladies or therapies. *Parasitol Res*. 2015;114:359–77.
- [39] Zhang Y, He P, Pan L, et al. Immunomodulatory effect of earthworm protein autolysates on Cyclophosphamide (CTX)-Induced immunosuppressed mice. *Food Biosci*. 2023;56:103297.
- [40] Cho IH, Choi ES, Lim HG, Lee HH. Purification and characterization of six fibrinolytic serine-proteases from earthworm *Lumbricus rubellus*. *J Biochem Mol Biol*. 2004;37:199–205.
- [41] Verma MK, Pulicherla KK. Broad substrate affinity and catalytic diversity of fibrinolytic enzyme from *pheretima posthumous*-purification and molecular characterization study. *Int J Biol Macromol*. 2017;95:1011–21.
- [42] Zhao R, Ji JG, Tong YP, Chen Q, Pu H, Ru BG. Isolation and identification of proteins with anti-tumor and fibrinolysin kinase activities from *Eisenia foetida*. *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)*. 2002;34:576–82.
- [43] Bi XJ, Guo HW, Ning W, et al. Extraction and isolation of the anti-tumor protein components from earthworm (*Eisenia foetida andrei*) and the anti-tumor activity. *Chin J Biochem Mol Biol*. 2003;39:227–34.
- [44] Xichun Z. Purification and characterization of two antibacterial peptides from. *J Dent Prev Treat*. 1999;06:955.
- [45] Li C, Chen M, Li X, Yang M, Wang Y, Yang X. Purification and function of two analgesic and anti-inflammatory peptides from coelomic fluid of the earthworm, *Eisenia foetida*. *Peptides*. 2017;89:71–81.
- [46] Oumi T, Ukena K, Matsushima O, et al. The GGNG peptides: novel myoactive peptides isolated from the gut and the whole body of the earthworms. *Biochem Biophys Res Commun*. 1995;216:1072–8.
- [47] Cheng F, Zhi-Zhong HE, Feng-Rong Z, Mei S. Purification by FPLC and activity of fibrinolytic enzyme from *pheretima guillemi*. *Pharm Biotechnol*. 2004;11:45–8.
- [48] Chen Z, Reddy G, Hahin R. The isolation and purification of two peptides from the venom of *buthus martensii karsch*. *Toxicon*. 2000;38:1817–32.
- [49] Olamendi-Portugal T, Csoti A, Jimenez-Vargas JM, Gomez-Lagunas F, Panyi G, Possani LD. Pi5 and Pi6, two undescribed peptides from the venom of the scorpion *Pandinus imperator* and their effects on K(+) channels. *Toxicon*. 2017;133:136–44.
- [50] Zhou XH, Yang D, Zhang JH, Liu CM, Lei KJ. Purification and N-terminal partial sequence of anti-epilepsy peptide from venom of the scorpion *Buthus martensii Karsch*. *Biochem J*. 1989;257:509–17.
- [51] Peng K, Kong Y, Zhai L, et al. Two novel antimicrobial peptides from centipede venoms. *Toxicon*. 2010;55:274–9.
- [52] Wenhua R, Shuangquan Z, Daxiang S, Kaiya Z, Guang Y. Induction, purification and characterization of an antibacterial peptide scolopendrin I from the venom of centipede *Scolopendra subspinipes mutilans*. *Indian J Biochem Biophys*. 2006;43:88–93.
- [53] Yoo WG, Lee JH, Shin Y, et al. Antimicrobial peptides in the centipede *Scolopendra subspinipes mutilans*. *Funct Integr Genomics*. 2014;14:275–83.
- [54] Choi H, Hwang JS, Lee DG. Antifungal effect and pore-forming action of lactoferricin B like peptide derived from centipede *Scolopendra subspinipes mutilans*. *Biochim Biophys Acta*. 2013;1828:2745–50.
- [55] Liu Z, Yuan K, Zhang R, et al. Cloning and purification of the first termicin-like peptide from the cockroach *Eupolyphaga sinensis*. *J Venom Anim Toxins Incl Trop Dis*. 2016;22:5.
- [56] Dong P, Zhang J, Wei Y, et al. Pharmacokinetics and pharmacodynamics of bioactive peptide LL8 from *Steleophaga plancyi* in rats. *Chin Tradit Herb Drug*. 2021;52:4607–13.
- [57] Wang H, Dong P, Liu X, et al. Active peptide AR-9 from *eupolyphaga sinensis* reduces blood lipid and hepatic lipid accumulation by restoring gut flora and its metabolites in a high fat diet-induced hyperlipidemia rat. *Front Pharmacol*. 2022;13:918505.
- [58] Kong Y, Xu C, He ZL, et al. A novel peptide inhibitor of platelet aggregation from stiff silkworm, *Bombyx batryticatus*. *Peptides*. 2014;53:70–8.
- [59] Wang H, Xu L, Dou Y, Wang J. *Bombyx batryticatus* cocoonase inhibitor separation, purification, and inhibitory effect on the proliferation of SMCC-7721 HeLa-derived cells. *Evid Based Complement Alternat Med*. 2022;2022:4064829.
- [60] Shang-Wei LI, Bai-Song Z, Juan DU. Isolation, purification, and detection of the antimicrobial activity of the antimicrobial peptide CcAMP1 from *Coridius chinensis* (Hemiptera: Dinidoridae). *Acta Entomol Sin*. 2015;06:610.
- [61] Morris R, Black KA, Stollar EJ. Uncovering protein function: from classification to complexes. *Essays Biochem*. 2022;66:255–85.
- [62] Jalil AT, Abdulhadi MA, Al-Ameer LR, et al. Peptide-based therapeutics in cancer therapy. *Mol Biotechnol*. 2024;66:2679–96.
- [63] Gustafsson O, Radler J, Roudi S, et al. Efficient peptide-mediated in vitro delivery of Cas9 RNP. *Pharmaceutics*. 2021;13:878.
- [64] Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. *J Immunol*. 2013;191:4895–901.
- [65] Wang L, Dong C, Li X, Han W, Su X. Anticancer potential of bioactive peptides from animal sources (Review). *Oncol Rep*. 2017;38:637–51.
- [66] Chen Q, Wu J, Li X, Ye Z, Yang H, Mu L. Amphibian-derived natural anticancer peptides and proteins: mechanism of action, application strategies, and prospects. *Int J Mol Sci*. 2023;24:13985.
- [67] Qiao L, Qi-Rui BI, Ning-Hua T. Research progress on proteins and peptides from earthworm. *Chin Tradit Herb Drugs*. 2019;01:252.
- [68] Czerwonka A, Fiolka MJ, Jedrzejewska K, Jankowska E, Zajac A, Rzeski W. Pro-apoptotic action of protein-carbohydrate fraction isolated from coelomic fluid of the earthworm *Dendrobaena veneta* against human colon adenocarcinoma cells. *Biomed Pharmacother*. 2020;126:110035.
- [69] Hakim MA, Yang S, Lai R. Centipede venoms and their components: resources for potential therapeutic applications. *Toxins*. 2015;7:4832–51.
- [70] Han Y, Kamau PM, Lai R, Luo L. Bioactive peptides and proteins from centipede venoms. *Molecules*. 2022;27:4423.
- [71] Lee JH, Kim IW, Kim SH, et al. Anticancer activity of the antimicrobial peptide scolopendrasin VII derived from the centipede, *scolopendra subspinipes mutilans*. *J Microbiol Biotechnol*. 2015;25:1275–80.
- [72] Zhao H, Li Y, Wang Y, et al. Antitumor and immunostimulatory activity of a polysaccharide-protein complex from *Scolopendra subspinipes mutilans* L. Koch in tumor-bearing mice. *Food Chem Toxicol*. 2012;50:2648–55.
- [73] Ding J, Chua P-J, Bay B-H, Gopalakrishnakone P. Scorpion venoms as a potential source of novel cancer therapeutic compounds. *Exp Biol Med (Maywood)*. 2014;239:387–93.
- [74] Yuan H, Kaifu X, Zhi W. Study on proliferation inhibition effects of *buthus martensii karsch* venom on human colon adenocarcinoma cell line Caco-2 in vitro. *Shandong Agric Sci*. 2016;12:136.
- [75] Tan J, Tian Y, Cai R, Yi T, Jin D, Guo J. Antiproliferative and proapoptotic effects of a protein component purified from *aspongopus chinensis dallas* on cancer cells in vitro and in vivo. *Evid Based Complement Alternat Med*. 2019;2019:8934794.
- [76] Skalny AV, Kushlinskii NE, Korobeinikova TV, et al. Zinc, copper, copper-to-zinc ratio, and other biometals in blood serum and tumor tissue of patients with colorectal cancer. *Biometals*. 2025.

- [77] Islam MR, Akash S, Jony MH, et al. Exploring the potential function of trace elements in human health: a therapeutic perspective. *Mol Cell Biochem.* 2023;478:2141–71.
- [78] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell.* 2012;149:1060–72.
- [79] Yan H, Talty R, Aladelokun O, Bosenberg M, Johnson CH. Ferroptosis in colorectal cancer: a future target? *Br J Cancer.* 2023;128:1439–51.
- [80] Yan H, Talty R, Johnson CH. Targeting ferroptosis to treat colorectal cancer. *Trends Cell Biol.* 2023;33:185–8.
- [81] Hoffmann FW, Hashimoto AC, Shafer LA, Dow S, Berry MJ, Hoffmann PR. Dietary selenium modulates activation and differentiation of CD4+ T cells in mice through a mechanism involving cellular free thiols. *J Nutr.* 2010;140:1155–61.
- [82] Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. *Proc Nutr Soc.* 2005;64:527–42.
- [83] Rustum YM, Chintala S, Durrani FA, Bhattacharya A. Non-coding micro RNAs and hypoxia-inducible factors are selenium targets for development of a mechanism-based combination strategy in clear-cell renal cell carcinoma-bench-to-bedside therapy. *Int J Mol Sci.* 2018;19:3378.
- [84] Fischer JL, Mihelc EM, Pollok KE, Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. *Mol Cancer Ther.* 2007;6:355–61.
- [85] Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. *Cancer Res.* 2006;66:7136–42.
- [86] Hoffmann PR, Berry MJ. The influence of selenium on immune responses. *Mol Nutr Food Res.* 2008;52:1273–80.
- [87] Hughes DJ, Fedirko V, Jenab M, et al. Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. *Int J Cancer.* 2015;136:1149–61.
- [88] Zheng X, Wu F, Lin X, Shen L, Feng Y. Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine. *Drug Deliv.* 2018;25:398–416.
- [89] Di L, Shi Y-N, Yan Y-M, et al. Nonpeptide small molecules from the insect *Aspongopus chinensis* and their neural stem cell proliferation stimulating properties. *RSC Adv.* 2015;5:70985–91.
- [90] Ni LJ, Liu XF, Hu X, Lin WZ, Xu HF, Yu LS. Research progress on the chemical composition of tubiechong. *Chin Arch Tradit Chin Med.* 2012;7:1–18.
- [91] Song YJ, Zou HC, Weng X, Ju JH. Research progress on chemical constituents and pharmacological activities of small molecule compounds in scorpions. *Zhongguo Zhong Yao Za Zhi.* 2024;49:661–70.
- [92] Zhang KY, Zhang YQ, Yang CM, et al. Research progress on processing history evolution, chemical constituents, and pharmacological action of *Scorpio*. *Zhongguo Zhong Yao Za Zhi.* 2024;49:868–83.
- [93] Bevilacqua E, Cruzat V, Singh I, Rose-Meyer RB, Panchal SK, Brown L. The potential of spent coffee grounds in functional food development. *Nutrients.* 2023;15:994.
- [94] Sun Q, Tao Q, Ming T, et al. Berberine is a suppressor of Hedgehog signaling cascade in colorectal cancer. *Phytomedicine.* 2023;114:154792.
- [95] Li SY, Shi CJ, Fu WM, Zhang JF. Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt/ β -catenin regulatory axis in colorectal cancer. *J Pharm Pharmacol.* 2023;75:129–38.
- [96] Xie J, Zhang D, Liu C, Wang L. A periodic review of chemical and pharmacological profiles of Tubiechong as insect Chinese medicine. *RSC Adv.* 2021;11:33952–68.
- [97] Jiang HL, Luo XH, Wang XZ, et al. New isocoumarins and alkaloid from Chinese insect medicine, *Eupolyphaga sinensis* Walker. *Fitoterapia.* 2012;83:1275–80.
- [98] Seeff LB. Herbal hepatotoxicity. *Clin Liver Dis.* 2007;11:577–96, vii.
- [99] Hasan S, Hassan K. Proteinuria associated with centipede bite. *Pediatr Nephrol.* 2005;20:550–1.
- [100] Liu X, Chen H, Zhong D. Study of anti-tumorous effect in vitro of extract of centipede on Bel-7404 cell of hepatocellular carcinoma. *Mod J Integr Tradit Chin West Med.* 2009;32:3935.